Skip to main content
S&P 5007,720.39-0.30%DOW52,342.56-0.25%NASDAQ26,184.72-1.38%BTC$77,460.00-3.31%ETH$2,239.04-3.65%GOLD$3,988.60-1.06%OIL$104.07+2.03%
Smart Investors Daily
SID Premium
EN

NASDAQ · ENTX

Entera Bio Ltd.

Healthcare · Biotechnology

$3.12

Up+$0.02 (+0.65%)

Updated Oct 30, 2026, 10:58 AM

SID Score

5.8/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
101.79M
P/E ratio
-41.77
Dividend yield
0.00%
52-week range
$0.91 – $4.20
Volume
140.95K
Avg. volume
154.41K

Price performance · ENTX

ENTX price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 29, 2026

ENTX closed at $3.12 after 21 trading sessions, up 7.96% for the selected period.

Last close
$3.12
Period change
+7.96%
Period low
$2.49
Period high
$3.12
Daily close
View OHLC price history
ENTX OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 29, 2026$3.08$3.189$3.01$3.12140.95K
Oct 28, 2026$3.05$3.195$3.005$3.10181.56K
Oct 27, 2026$2.85$3.13$2.81$3.06203.53K
Oct 26, 2026$2.90$2.90$2.80$2.86232.47K
Oct 23, 2026$2.99$3.02$2.86$2.92256.93K
Oct 22, 2026$3.01$3.04$2.9007$3.02629.48K
Oct 21, 2026$3.12$3.20$2.96$3.05784.6K
Oct 20, 2026$2.79$3.26$2.79$3.02791.93K
Oct 19, 2026$2.66$2.97$2.62$2.94953.14K
Oct 16, 2026$2.72$2.75$2.62$2.68572.89K
Oct 15, 2026$2.49$2.82$2.49$2.771.45M
Oct 14, 2026$2.47$2.565$2.46$2.50784.49K
Oct 13, 2026$2.65$2.65$2.435$2.49755.3K
Oct 12, 2026$2.66$2.775$2.639$2.65305.69K
Oct 9, 2026$2.51$2.72$2.505$2.661.58M
Oct 8, 2026$2.48$2.52$2.45$2.50421.03K
Oct 7, 2026$2.52$2.58$2.45$2.51679.48K
Oct 6, 2026$2.66$2.67$2.53$2.53621.17K
Oct 5, 2026$2.89$2.89$2.62$2.621.25M
Oct 2, 2026$2.89$2.90$2.82$2.86100.7K
Oct 1, 2026$2.89$3.00$2.81$2.89640.88K

Latest ENTX news

The latest Smart Investors Daily articles mentioning ENTX.

Stock researchCompany · Overview

ENTX research

Overview

Company profile and research snapshot.

Company profile

Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
ENTX recent ratings
DateFirmRatingTarget
Sep 25, 2026GuggenheimBuy—
Sep 22, 2026Cantor FitzgeraldOverweight—
Sep 18, 2026Leerink PartnersOutperform—
Apr 27, 2026HC Wainwright & Co.Buy—
Feb 9, 2026HC Wainwright & Co.Buy—
Open full forecast

News briefing

Generated Oct 30, 2026, 11:12 AM

Why Is ENTX Up Today?

Entera Bio Ltd. is trading modestly higher today following the announcement of a strategic board appointment that signals the company's commitment to strengthening its research and development capabilities. The appointment of Dr. Juan Camilo Arjona Ferreira, a global R&D leader, suggests management confidence in advancing the company's pipeline and may provide investors with reassurance about operational direction.

    Bottom line: Today's modest gain reflects cautious optimism around Entera's board strengthening, though the move alone is unlikely to drive significant momentum without accompanying clinical or commercial milestones. Investors should monitor upcoming pipeline announcements and clinical data as key catalysts that could validate the strategic direction signaled by this appointment.

    Yahoo · Oct 27, 2026

    Entera Appoints Global Research and Development Leader Dr. Juan Camilo Arjona Ferreira to Its Board of Directors

    Dr. Arjona Ferreira currently serves as Head of Research and Development and Chief Medical Officer at Organon & Co. (NYSE: OGN) He joins Entera with two decades of clinical development, regulatory execution, and women’s health leadership with roles at Myovant, Shionogi and Merck prior to Organon TEL AVIV, Israel, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced the appointment of clinical l

    Yahoo · Oct 13, 2026

    Entera Presents Markedly Enhanced Anabolic Effects of EB613 (First-in-Class Oral PTH(1-34) Tablet) in Postmenopausal Women with Osteoporosis at High Risk of Fracture and Showcases Phase 3 Design at ASBMR 2026 Annual Meeting

    Post-hoc Phase 2 data show greater bone mineral density (BMD) gains and anabolic effect with EB613 in postmenopausal women with baseline T-scores of ≤-2.5 (osteoporosis) versus T-scores of >-2.5 (osteopenia) These findings support the potential benefit of EB613 in postmenopausal women with osteoporosis at high risk for fracture - consistent with the study population to be enrolled in Entera’s Phase 3 study TEL AVIV, Israel, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Enter

    AI research layers

    Interpretive context generated from the platform’s current data sources.

    No results

    AI research layers have not been published yet.

    Featured By